Effect of the sodium-glucose cotransporter-2 inhibitor, DWP16001, as an add-on therapy to insulin for diabetic dogs: A pilot study.

Ju-Hyun AnHan-Sol ChoiJi-Soo ChoiHyun-Woo LimWan HuhYe-In OhJoon Seok ParkJumi HanSoo LimChae-Young LimTae-Hee KimJae-Bong MoonHwa Young Youn

Published in: Veterinary medicine and science (2024)

When DWP16001, an SGLT2 inhibitor, was supplied to dogs with type 1 diabetes, no adverse effects were observed, and it was confirmed that the administered insulin dose can be reduced in controlling blood glucose.

Keyphrases

blood glucose
glycemic control
type diabetes
blood pressure
insulin resistance
metabolic syndrome
skeletal muscle
mesenchymal stem cells